Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: A single center experience

Yoichiro Nuki, Motohiro Esaki, Kouichi Asano, Yuji Maehata, Junji Umeno, Tomohiko Moriyama, Shotaro Nakamura, Takayuki Matsumoto, Takanari Kitazono

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: Both tacrolimus (Tac) and infliximab (IFX) are effective for moderate-to-severe ulcerative colitis (UC). The aim of this study was to compare the therapeutic efficacy and safety of both drugs. Materials and methods: We performed a retrospective analysis of 46 patients with moderate-to-severe UC who were treated either by Tac (n = 21) or IFX (n = 25). We compared the remission and response rates for 10 weeks between the two groups. In patients who achieved a clinical response, the subsequent relapse rate was compared. The overall adverse events were also compared between the two groups. Results: The remission and response rates at week 10 did not differ between patients treated with Tac (67% and 86%, respectively) and patients treated with IFX (76% and 92%, respectively). Among 41 patients showing a clinical response, eight of 23 patients treated with IFX and eight of 18 patients treated with Tac showed a subsequent relapse. The risk of relapse was not different between the two groups. While no serious adverse events were observed, the incidence of adverse events was higher in patients treated with Tac than in those treated with IFX. Conclusion: Tac and IFX may be equally efficacious for the induction and maintenance of remission in patients with UC while minor adverse events are more frequent with the former treatment.

Original languageEnglish
Pages (from-to)700-705
Number of pages6
JournalScandinavian Journal of Gastroenterology
Volume51
Issue number6
DOIs
Publication statusPublished - Jun 2 2016

Fingerprint

Tacrolimus
Ulcerative Colitis
Safety
Therapeutics
Recurrence
Infliximab
Remission Induction
Maintenance
Incidence

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis : A single center experience. / Nuki, Yoichiro; Esaki, Motohiro; Asano, Kouichi; Maehata, Yuji; Umeno, Junji; Moriyama, Tomohiko; Nakamura, Shotaro; Matsumoto, Takayuki; Kitazono, Takanari.

In: Scandinavian Journal of Gastroenterology, Vol. 51, No. 6, 02.06.2016, p. 700-705.

Research output: Contribution to journalArticle

Nuki, Yoichiro ; Esaki, Motohiro ; Asano, Kouichi ; Maehata, Yuji ; Umeno, Junji ; Moriyama, Tomohiko ; Nakamura, Shotaro ; Matsumoto, Takayuki ; Kitazono, Takanari. / Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis : A single center experience. In: Scandinavian Journal of Gastroenterology. 2016 ; Vol. 51, No. 6. pp. 700-705.
@article{da9550ec20cb4a9b94f8580fd09c1460,
title = "Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: A single center experience",
abstract = "Objective: Both tacrolimus (Tac) and infliximab (IFX) are effective for moderate-to-severe ulcerative colitis (UC). The aim of this study was to compare the therapeutic efficacy and safety of both drugs. Materials and methods: We performed a retrospective analysis of 46 patients with moderate-to-severe UC who were treated either by Tac (n = 21) or IFX (n = 25). We compared the remission and response rates for 10 weeks between the two groups. In patients who achieved a clinical response, the subsequent relapse rate was compared. The overall adverse events were also compared between the two groups. Results: The remission and response rates at week 10 did not differ between patients treated with Tac (67{\%} and 86{\%}, respectively) and patients treated with IFX (76{\%} and 92{\%}, respectively). Among 41 patients showing a clinical response, eight of 23 patients treated with IFX and eight of 18 patients treated with Tac showed a subsequent relapse. The risk of relapse was not different between the two groups. While no serious adverse events were observed, the incidence of adverse events was higher in patients treated with Tac than in those treated with IFX. Conclusion: Tac and IFX may be equally efficacious for the induction and maintenance of remission in patients with UC while minor adverse events are more frequent with the former treatment.",
author = "Yoichiro Nuki and Motohiro Esaki and Kouichi Asano and Yuji Maehata and Junji Umeno and Tomohiko Moriyama and Shotaro Nakamura and Takayuki Matsumoto and Takanari Kitazono",
year = "2016",
month = "6",
day = "2",
doi = "10.3109/00365521.2016.1138239",
language = "English",
volume = "51",
pages = "700--705",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis

T2 - A single center experience

AU - Nuki, Yoichiro

AU - Esaki, Motohiro

AU - Asano, Kouichi

AU - Maehata, Yuji

AU - Umeno, Junji

AU - Moriyama, Tomohiko

AU - Nakamura, Shotaro

AU - Matsumoto, Takayuki

AU - Kitazono, Takanari

PY - 2016/6/2

Y1 - 2016/6/2

N2 - Objective: Both tacrolimus (Tac) and infliximab (IFX) are effective for moderate-to-severe ulcerative colitis (UC). The aim of this study was to compare the therapeutic efficacy and safety of both drugs. Materials and methods: We performed a retrospective analysis of 46 patients with moderate-to-severe UC who were treated either by Tac (n = 21) or IFX (n = 25). We compared the remission and response rates for 10 weeks between the two groups. In patients who achieved a clinical response, the subsequent relapse rate was compared. The overall adverse events were also compared between the two groups. Results: The remission and response rates at week 10 did not differ between patients treated with Tac (67% and 86%, respectively) and patients treated with IFX (76% and 92%, respectively). Among 41 patients showing a clinical response, eight of 23 patients treated with IFX and eight of 18 patients treated with Tac showed a subsequent relapse. The risk of relapse was not different between the two groups. While no serious adverse events were observed, the incidence of adverse events was higher in patients treated with Tac than in those treated with IFX. Conclusion: Tac and IFX may be equally efficacious for the induction and maintenance of remission in patients with UC while minor adverse events are more frequent with the former treatment.

AB - Objective: Both tacrolimus (Tac) and infliximab (IFX) are effective for moderate-to-severe ulcerative colitis (UC). The aim of this study was to compare the therapeutic efficacy and safety of both drugs. Materials and methods: We performed a retrospective analysis of 46 patients with moderate-to-severe UC who were treated either by Tac (n = 21) or IFX (n = 25). We compared the remission and response rates for 10 weeks between the two groups. In patients who achieved a clinical response, the subsequent relapse rate was compared. The overall adverse events were also compared between the two groups. Results: The remission and response rates at week 10 did not differ between patients treated with Tac (67% and 86%, respectively) and patients treated with IFX (76% and 92%, respectively). Among 41 patients showing a clinical response, eight of 23 patients treated with IFX and eight of 18 patients treated with Tac showed a subsequent relapse. The risk of relapse was not different between the two groups. While no serious adverse events were observed, the incidence of adverse events was higher in patients treated with Tac than in those treated with IFX. Conclusion: Tac and IFX may be equally efficacious for the induction and maintenance of remission in patients with UC while minor adverse events are more frequent with the former treatment.

UR - http://www.scopus.com/inward/record.url?scp=84957998734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957998734&partnerID=8YFLogxK

U2 - 10.3109/00365521.2016.1138239

DO - 10.3109/00365521.2016.1138239

M3 - Article

C2 - 26818468

AN - SCOPUS:84957998734

VL - 51

SP - 700

EP - 705

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 6

ER -